Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.

Abstract: Disclosed herein are antibodies to SARS-COV-2 antigens and recombinant nucleic acid sequences that encode the SARS-COV-2 antibodies. The disclosure also provides a method of preventing and/or treating a SARS-COV-2 infection or disease or disorder associated with SARS-COV-2 infection (e.g., COVID-19) in a subject using said compositions and methods.

Abstract: Disclosed herein are nucleic acid encoded Fc-modified antibodies and methods of use of the same for the treatment of diseases and disorders.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets PCSK9. The disclosure also provides a method of preventing and/or treating disease, such as cardiovascular disease or hypercholesterolemia, in a subject using the composition of the invention.

Abstract: Computer generated speech can be generated for cross-lingual natural language textual data streams by utilizing a universal phoneme set. In a variety of implementations, the natural language textual data stream includes a primary language portion in a primary language and a secondary language portion that is not in the primary language. Phonemes corresponding to the secondary language portion can be determined from a set of phonemes in a universal data set. These phonemes can be mapped back to a set of phonemes for the primary language. Audio data can be generated for these phonemes to pronounce the secondary language portion of the natural language textual data stream utilizing phonemes associated with the primary language.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Plasmodium parasitic antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Plasmodium parasitic infection in a subject using said composition and method of generation.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.

Abstract: The present invention disclosed an intradermal vaccine that protects against Middle East Respiratory Syndrome coronavirus (MERS-CoV). In one embodiment, the vaccine is a DNA vaccine. In one embodiment, the vaccine comprises an antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. The present invention also discloses methods of treating or preventing MERS-CoV in a subject in need thereof by administering the vaccine intradermally to the subject.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.

Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

Abstract: Disclosed herein is a vaccine comprising a Coronavirus disease 2019 (COVID-19) antigen in a combination with an immunoglobulin from post-exposure treatment. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

Abstract: Disclosed herein are combinations of inhibitors of B cell maturation and recombinant nucleic acid molecules encoding synthethic antibodies, and their use for extending the duration of circulating synthetic antibodies and for treating diseases and disorders.

Abstract: Computer generated speech can be generated for cross-lingual natural language textual data streams by utilizing a universal phoneme set. In a variety of implementations, the natural language textual data stream includes a primary language portion in a primary language and a secondary language portion that is not in the primary language. Phonemes corresponding to the secondary language portion can be determined from a set of phonemes in a universal data set. These phonemes can be mapped back to a set of phonemes for the primary language. Audio data can be generated for these phonemes to pronounce the secondary language portion of the natural language textual data stream utilizing phonemes associated with the primary language.

Abstract: Provided herein are methods of inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof by administering an immunogenic composition to the subject, wherein the subject exhibits: an increase in antigen-specific cellular immune response as measured by Interferon-gamma (IFN-?) Enzyme-linked Immunospot (ELISpot) assay relative to baseline; and/or an increase in neutralizing antibody response as measured by a pseudovirus neutralizing assay relative to baseline.